Introduction
Leading pharmaceutical company receives U.S. FDA approval for Rivaroxaban 1 mg/mL oral suspension, indicated for treating pediatric venous thromboembolism and congenital heart disease, with manufacturing at a Chhatrapati Sambhajinagar facility in India.
Also Read: BEL: Stock jumps after securing additional orders worth ₹1,092 Cr
Share price movement of Lupin
On October 01, 2025, Lupin Ltd opened at ₹1,929.95, up 1.04% from its previous close of ₹1,910.15. The stock reached a high of ₹1,984.90 and a low of ₹1,926.10. By 11:57 AM, it traded at ₹1,969.20, a 3.09% increase, with a market cap of ₹89,944.76 crore.
Lupin Gets U.S. FDA Approval for Rivaroxaban
Lupin Limited has received U.S. FDA approval for its Rivaroxaban for Oral Suspension, 1 mg/mL, under an Abbreviated New Drug Application, bioequivalent to Xarelto® oral suspension.
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India. It is indicated for treating venous thromboembolism and reducing recurrent VTE risk in pediatric patients.
Rivaroxaban for Oral Suspension is also approved for thromboprophylaxis in pediatric patients with congenital heart disease post-Fontan procedure. Estimated U.S. annual sales of the reference product are USD 11 million.
Stock performance of Lupin for Period of 1 week, 6 months, and 1 year
Lupin Ltd delivered a -4.00% return over the past week and declined by -3.03% over the past six months. The stock fell by -12.9% over the past year.
Also Read: Globus Spirits: Stock in focus after unveiling world’s first premium vodka
Shareholding pattern of Lupin
| Particulars | Jun 2025 | Mar 2025 | Dec 2024 |
| Promoter | 46.90% | 46.90% | 47.00% |
| FII | 21.30% | 21.50% | 22.00% |
| DII | 25.60% | 25.40% | 24.70% |
| Public | 6.30% | 6.20% | 6.30% |
About Lupin
Lupin Limited (NSE: LUPIN) is a global pharmaceutical leader headquartered in Mumbai, specializing in branded and generic formulations, complex generics, biotechnology, and APIs, with 15 manufacturing sites, seven research centers, and over 24,000 employees.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Lupin Ltd share price going up today?
A: Lupin Ltd share price rose after receiving U.S. FDA approval for its Rivaroxaban for Oral Suspension, 1 mg/mL.
Q: What does Lupin Ltd specialize in?
A: Lupin Ltd specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients globally.
Q: How much stake do promoters hold in Lupin Ltd stock?
A: Promoters hold a 46.90% stake in Lupin Ltd, reflecting significant ownership and control in the company.
